Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenon Medical, Inc. (NASDAQ: TNON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tenon is a medical device company focused on sacroiliac (SI) joint and sacro-pelvic fusion systems, including the Catamaran and SImmetry platforms. Its filings give investors detailed information on capital raising transactions, acquisitions, equity compensation, governance decisions and financial reporting related to this sacro-pelvic fusion business.
Recent Form 8‑K filings describe material events such as the November 10, 2025 securities purchase agreements for an at‑the‑market PIPE financing, in which Tenon agreed to issue common stock and common stock purchase warrants, generating approximately $2.85 million in gross proceeds for working capital and general corporate purposes. Another 8‑K filed on August 6, 2025 outlines the asset purchase agreements for the SiVantage (SImmetry business) and SIMPL Medical portfolios, including cash, equity, royalty and earnout components, along with related employment agreements for key executives joining Tenon.
Filings also cover equity and governance matters. An 8‑K dated October 16, 2025 reports the issuance of restricted stock units to Tenon’s directors and officers under the 2022 Equity Incentive Plan, with specified vesting schedules. An 8‑K filed September 23, 2025 details the results of the 2025 Annual Meeting of Stockholders, including election of directors, approval of warrant exercisability, amendments to the equity incentive plan and ratification of the independent auditor. An 8‑K/A filed October 17, 2025 provides financial statements of SiVantage and unaudited pro forma condensed combined financial information reflecting the acquisition.
Through Tenon’s periodic reports and accompanying exhibits, investors can review condensed balance sheets, statements of operations and comprehensive loss, and pro forma financials that show how acquisitions affect the company’s financial position. Stock Titan enhances this information with AI-powered summaries that explain key terms in plain language, highlight important elements of PIPE financings, asset purchase agreements and equity awards, and help users quickly identify items such as warrant terms, earnout structures and royalty obligations. The filings page also surfaces insider-related equity grants reported in 8‑Ks, giving a clearer view of how management and directors are compensated through stock and restricted stock units.
By combining real-time EDGAR updates with AI-generated insights, the Tenon Medical filings section helps users understand how capital structure changes, acquisitions of sacro-pelvic technologies and governance decisions relate to the company’s strategy in SI joint fusion and sacro-pelvic fixation.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.
Tenon Medical, Inc. has rescheduled its previously adjourned Annual Meeting to be held virtually on September 18, 2025, at 10:30 a.m. Pacific Time. The meeting had been adjourned on July 23, 2025 and August 20, 2025.
Only shareholders of record at the close of business on August 22, 2025 are entitled to notice and to vote. Stockholders must use a Virtual Control Number to participate and vote electronically, with additional steps required for those holding shares in “street name.” The company urges shareholders to vote before September 16, 2025 to ensure their votes are received and counted.
Nathaniel A. Grawey, Chief Commercial Officer of Tenon Medical (TNON), reported beneficial ownership on a Form 3. He directly holds 138,114 shares of common stock, which are stated to be subject to a vesting schedule and non-transferable, and has an indirect interest in 175,383 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Grawey holds 24.69% of that company.
Tenon Medical, Inc. reported quarterly revenue of $564,000 and six‑month revenue of $1.29 million, down from $901,000 and $1.62 million a year earlier, driven by fewer procedures using The Catamaran System. Gross profit fell and margins compressed, while the company recorded a net loss of $2.769 million for the quarter and $6.385 million for the six months, contributing to an accumulated deficit of $75.1 million. Cash and cash equivalents totaled $7.846 million at June 30, 2025, bolstered by $6.2 million of net financing in the first half of 2025.
Management discloses substantial doubt about the company’s ability to continue as a going concern for the next 12 months and plans to seek additional capital. Subsequent events include the acquisitions of SImmetry (closed Aug 1, 2025) and SIMPL (closed Aug 4, 2025), which transfer IP and product assets for cash, shares and royalty arrangements; the transactions also include executive hires with equity compensation. The company reported a material weakness in internal controls related to segregation of duties.
Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, filed a Form 3 reporting beneficial ownership related to an 08/01/2025 event. He directly holds 138,114 common shares (noted as subject to a vesting schedule and non-transferable) and has an indirect interest of 350,765 shares through SiVantage, Inc. SiVantage owns 710,300 shares and Geist holds a 49.38% equity interest in that company.
Tenon Medical acquired substantially all assets and intellectual property of SiVantage's SImmetry business and of SIMPL, including technologies for sacropelvic fixation and posterior sacroiliac implants. Consideration to SiVantage included $750,000 cash, 710,300 shares of common stock (with 473,533 shares held by Tenon for one year as indemnity security), tiered royalties and contingent payments, and potential earnout equity. Royalties for SImmetry start at 15% then drop to 10% (capped at $5.0 million); SIMPL royalties begin at 30% (reducing to 20% after aggregate payments exceed $20.0 million). SiVantage and two related executives together beneficially own 986,528 shares, about 12.5% of outstanding stock, and two SiVantage principals were appointed to Tenon management and received 138,114 shares each.